As we’ve noted quite a few times before, Brazil’s healthcare system is not the shiny example that its diplomats (and the WHO) often present to the world. This article (from a competitor, the Research Partnership) does a very good  job of summarising the issues around Brazil as a pharmaceutical market. It doesn’t talk about the country’s great public health successes (immunisation coverage and accessible, effective HIV treatment, for example); its hardball tactics in international health politics (where its officials frequently threaten to confiscate intellectual property as a way of securing tech transfer or exceptionally low prices) or; the inefficiencies of its state pharma and vaccines sector (which means that Brazilian generics often cost more than generics in the US or Canada and that its vaccines are, apparently, produced with big subsidies). It does, though, explain well the bizarre system in which many chronically-ill patients have to sue to get treated